Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Venous thromboembolism

Use of anti-clotting drugs before, during or after surgery is not for everyone, study results show

Researchers question the practice of giving anticoagulants routinely to patients undergoing surgery.

Surgeons performing general surgery

Source: Shutterstock

The researchers say that their results throw into question the practice that all patients who are to undergo surgery must be given anticoagulants regardless of their VTE risk

Giving anti-clotting drugs routinely to all patients as prophylaxis against developing venous thromboembolism (VTE) after surgery may be unnecessary in as many as 75% of cases, according to research published in the Annals of Surgery[1] (online, 19 January 2017).

The study throws into question the common practice that all patients who are to undergo general surgery should be given anticoagulants regardless of their individual risk of developing a VTE, the researchers say.

“These data argue strongly for a precision medicine approach to VTE chemoprophylaxis, where the intervention is guided by the risk/benefit relationship at the patient level. These data also provide strong evidence about who should not receive chemoprophylaxis,” the team says.

The researchers base their conclusions on an analysis of 14,776 patient records from 13 studies when they set out to discover which surgical patients were more likely and least likely to benefit from being given anticoagulants. All the studies included data on patients with postoperative VTE and/or bleeding events with and without chemoprophylaxis (the studies also included mechanical prophylaxis).

The team took into account the patients’ Caprini score – the commonly used assessment tool that calculates an individual’s risk of developing a VTE. A patient with a 0­–2 Caprini score has a small risk of developing a VTE, but this rises as the number of risk factors a patient has increases.

The researchers discovered that patients with Caprini scores of 7 to 8 and greater than 8 had a significant reduction in peri-operative VTE when chemoprophylaxis was received. This had previously been shown in plastic and reconstructive surgery, but never in the general surgical population, they say.

But patients with Caprini scores of 6 or under — who accounted for 75% of the patient population — did not have a “significant” VTE risk reduction with chemoprophylaxis.

This study also looked at bleeding risk in response to chemoprophylaxis when stratified by VTE risk score, and shows that there is no clear association between Caprini score and risk for bleeding.

The research was welcomed by Sotiris Antoniou, consultant pharmacist in cardiovascular medicine, Barts Health NHS Trust in London.

Antoniou, who is also honorary senior research associate at UCL School of Pharmacy, says: “As we move into a more personalised medicine approach, this [study] provides a reminder that all medicines pose a risk.

“VTE prophylaxis in surgical patients currently falls under the ‘one-size-fits-all’ approach and using a risk stratification score (for example, Caprini) may allow us to fine tune the need and identify some individuals who may not receive any tangible benefit from receiving pharmacological VTE prophylaxis, yet be exposed to bleeding risk.

“For the past decade the drive in the UK has been to promote VTE prophylaxis, recognising that as many as 70% of patients assessed to be at medium or high risk of developing deep vein thrombosis did not receive any form of mechanical or pharmacological VTE prophylaxis, contributing to 25,000 deaths from preventable hospital-acquired VTE every year.”

He says that VTE guidance from the UK’s health technology assessment body, the National Institute for Health and Care Excellence, does provide reference to bleeding considerations by highlighting risk factors. “This paper further complements this to continue the journey for an individualised approach.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202236

Readers' comments (1)

  • In 2002 I had my left hip replaced and was on Coumadin for 1 week. I don't think it was necessary as my blood is thin to begin with and it not subject to blood clots, etc. As a result, I ended up with headaches and muscle pain for a while. My fingertips (sometimes 9 at a time) and fingernails split and this remained a problem for over 18 months. Nine years later I took care of my mother for 6 months because she required open heart surgery. She was on Coumadin and just dispensing (touching) her Coumadin, brought back the headaches and body pain, along with a nasty black sore on my back. Also the splitting fingernails and finger tips returned and that lasted over a year. This stuff is ghastly and what it does to some people is beyond misery!!!!!

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Surgeons performing general surgery

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.